Premaitha expands prenatal product into two new markets

The AIM-listed medical developer said the contracts would expand Premaitha's customer base into new international markets, enabling more pregnant women to benefit from the "safety and accuracy" of the firm's IONA product.

Premaitha described IONA as the first CE-marked non-invasive prenatal screening product on the market.

"The high clinical standards and excellent customer support offered by Prenaitha's screening services team, coupled with the proven performance of the IONA test means we are able to provide pregnant women with the best possible screening test", said Premaitha CEO Stephen Little.

Premaitha did not disclose who the two new customers were.

The company initiated its Care Quality Commission-registered screening service in July last year, and in October opened a dedicated facility in response to customer demand for the IONA test.